vorasidenib
servier
['vorasidenib']
in patients with grade 2 idh-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention. #asco23 #asco2023 #oncology #meded #medtwitter 
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News